CEO인사말 1 페이지

본문 바로가기

사이트 내 전체검색

Company

Hucord for the benefit of mankind

Global leader of cord blood stem cell applications
based on humanism and technology

Hucord Co.,Ltd. concentrates on the development of advanced technology of cord blood,
which is seen as “Drug repository of 21st ”, and stem cells

Company

Hucord for the benefit of mankind

Global leader of cord blood stem cell applications based on humanism and technology

Hucord Co.,Ltd. concentrates on the development of advanced technology of cord blood, which is seen
as “Drug repository of 21st ”, and stem cells

Company

Hucord for the benefit of mankind

Featured in the prestigious Nature magazine as the world’s
one of six stem cell treatment companies

in 2003, successfully isolated stem cells from cord blood for the first time in the world. Hucord Co.,Ltd. possesses more than
10 original technology patents related to cord blood and cord blood stem cells, including cord blood cryopreservation, cord blood stem cell isolation
and culture, mixture method of mixed cord blood and peripheral blood without immune reaction and so on. In addition, Hucord Co.,Ltd.
published several papers with the results of clinical applications of cord blood stem cells in Buerger’s disease, liver cirrhosis etc.
Therefore, the technology and competitiveness acknowledged by international journal “Nature” and selected as Top 6 stem cell companies in the world.

Company

Hucord for the benefit of mankind

Featured in the prestigious Nature magazine as the world’s one of six stem cell treatment companies

in 2003, successfully isolated stem cells from cord blood for the first time in the world. Hucord Co.,Ltd. possesses more than 10 original technology patents related to cord blood and cord blood stem cells, including cord blood cryopreservation, cord blood stem cell isolation and culture, mixture method of mixed cord blood and peripheral blood without immune reaction and so on. In addition, Hucord Co.,Ltd. published several papers with the results of clinical applications of cord blood stem cells in Buerger’s disease, liver cirrhosis etc. Therefore, the technology and competitiveness acknowledged by international journal “Nature” and selected as Top 6 stem cell companies in the world.

History

Hucord’s challenge and innovation

  • 2000


    Establishment of Histostem.

    Information on human umbilical
    cord blood hematopoietic stem
    cell disclosed to the public
    for the first time

  • 2001


    World’s first to discover the
    existence of stem cells in human
    umbilical cord blood and
    differentiation into osteoblast.

    First cord blood bank in Korea to
    provide human umbilical cord
    blood to a foreign (Japanese)
    patient.

  • 2002


    Became the first and only cord
    blood bank in Korea
    to be granted international
    certification from AsiaCord.

  • 2003


    Succeeded in developing
    the technology for separation
    and cultivation of mesenchymal stem cells from cord blood.

    Succeeded in proliferation and
    differentiation of multipotent cells
    of human cord blood.

    Official announcement of the
    treatment results of liver cirrhosis.

  • 2004


    Successfully performed
    treatment in cerebral
    infarction, spinal palsy,
    Type II diabetes, multiple
    sclerosis, burger disease,
    cirrhosis, osteoporosis,
    primary biliary cirrhosis
    and hypertension.

  • 2005


    Treated an American
    patient suffering from
    spinal paralysis using
    cord blood stem cells.

    Transfused human
    umbilical cord blood for
    anemia patient in the
    University of California,
    San Francisco.

  • 2006


    36 emergency
    clinical trial results in
    animal experiments
    such as spinal
    paralysis.

  • 2007


    Gained authoritative
    interpretation from the
    Ministry of Food and
    Drug Safety on cord
    blood stem cell treatment

  • 2008


    Treated over 500
    incurable diseases

  • 2009


    Succeeded in treating a
    stroke patient who had
    no chance of revival.
    Developed human stem
    cell conditioned media
    (HSCM).

  • 2010


    Selected as the research
    institue of WPM project
    supported by the Ministry
    of Knowledge Economy
    with a grant of 1.25
    million dollars.

  • 2011


    Published a paper using the
    results from the preclinical trial of
    spinal paralysis treatment with
    human cord blood stem cells
    (J Neurological Science).

    Collected world’s largest amount
    of 90,000 cord blood units.

  • 2014

    Changed the company name to
    Hucord Co.,Ltd. and moved the
    headquarters to Bundang Gu,
    Seongnam City, Gyeonggi Do.

  • 2015


    Established a Hucord branch
    subsidiary in Hanoi, Vietnam.

    Released stem cell conditioned
    media cosmetics ‘Babycell Cream’,
    ‘Babycell Serum’ and ‘HSCM’.

  • 2016


    Signed MOU with Vietnam 108
    Military Central Hospital.

    Lectured in Vietnam 108
    Military Central Hospital in their
    60th year science seminar.

    Released stem cell conditioned
    media product ‘HSCM100SF’.

    Lectured in Japan JAAP 2016
    conference seminar.

  • 2017


    Lectured in Cord Blood World
    Europe 2017 conference that
    took place in London, United
    Kingdom.

    Lectured in Japan JAAP
    2017 conference seminar.

  • 2018


    Established a joint venture
    ‘Hucord-Vina’ in Hanoi, Vietnam.

    Released a stem cell
    conditioned media product
    ‘MORAN’.

  • 2019

    Released a stem cell
    conditioned media cosmetics
    product ‘HK0126’.

    Obtained a product license in
    Vietnam for ‘HSCM100’ and
    ‘MORAN’.

    Began exporting HSCM
    to the USA and Japan.

    Established a joint venture
    with a Chinese government
    agency ‘MTP’.

  • 2020


    Obtained CFDA license
    in China for ‘MORAN’
    and ‘HK0126’.

    Released a stem cell
    conditioned media cosmetics
    product, ‘INCORD’.

CI

Corporate Identity

  • Stem cells

    생명,건강

  • Humanism

    휴머니즘

  • Cord blood

    제대혈

Hucord’s CI means the professional medical service for happy and healthy life based on humanism.

Social Contribution

treatment of incurable and rare diseases

best to provide good quality cord blood

Hucord Co.,Ltd. is trying best to provide good quality cord blood
to patients suffered from intractable diseases like leukemia. And lead
public services by making connections with public welfare
foundations to provide cord blood to 200 blood cancer patients
without charge and free subscriptions to low-income families and multicultural families.

Social Contribution

treatment of incurable and rare diseases

best to provide good quality cord blood

Hucord Co.,Ltd. is trying best to provide good quality cord blood
to patients suffered from intractable diseases like leukemia. And lead
public services by making connections with public welfare
foundations to provide cord blood to 200 blood cancer patients
without charge and free subscriptions to low-income families and multicultural families.

Direction

  • 35-3, Soetgol-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea